OCT 11, 2018 10:30 AM PDT

Drug Targeting for Inflammatory Breast Cancer

Speaker
  • Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University
    Biography
      Dr. Kevin P. Williams, Ph.D. is an Associate Professor in the Department of Pharmaceutical Sciences and a faculty member of BRITE at North Carolina Central University. Dr. Williams has over 25 years combined experience in both academic and biopharmaceutical-based research with a focus on cancer and drug discovery. Dr. Williams received his B.Sc. in Biochemistry from the University of Bath in the UK and received his Ph.D. in Biochemistry from the University of Cambridge (UK). He completed his postdoctoral work at Massachusetts General Hospital and the Joslin Diabetes Center in Boston. Prior to joining NCCU in 2007, he spent six years as a Senior Scientist at Biogen in the Department of Protein Engineering and four years at Amphora Corp as Director of Enzyme Drug Discovery. At NCCU he has obtained NIH and DOD research support and mentored 12 Masters level graduate students. His lab currently focuses on identifying novel modulators of the hedgehog pathway. Dr. Williams serves as course director and main instructor for the undergraduate bioprocessing and graduate-level biomanufacturing classes. He is co-author of over 45 publications and co-inventor on 9 patents.

    Abstract

    Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype accounting for ~15% of all breast cancer deaths. IBC is characterized by Stage III or IV at diagnosis, no solid tumor, typically not detected by mammogram and rapid progression from onset of disease. The incidence of IBC is higher in younger patients and in women of African descent. There are limited treatment options for IBC. Targeted therapy with drugs that target HER1/2 (if the cancer is HER2-positive) e.g. the HER1/2 tyrosine kinase inhibitor lapatinib are one of the few treatment options but drug resistance is observed in the clinic. In the first project, we characterized a novel isogenic-derived progression model of lapatinib drug resistance and re-sensitization using the IBC cell line SUM149. In this study, lapatinib-resistant rSUM149 cells showed cross-resistance to a number of the drugs previously shown to act on the parental cells. The rSUM149 cells had increased levels of anti-apoptotic proteins, increased antioxidant expression, and decreased ability to accumulate reactive oxygen species (ROS), all of which lead to inhibition of drug-induced apoptosis. These results strengthen the need for novel strategies to modulate cellular redox to overcome drug resistance in IBC. In the second project, a major effort of our lab is to identify novel modulators of the hedgehog pathway in breast cancer. Dysregulation of the developmental Hedgehog (Hh) pathway is observed in many cancers with activation of the downstream Hh pathway effector GLI1 being linked to tumorigenesis and invasiveness in breast cancer including IBC. We have profiled a collection of GLI-directed small molecule antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of IBC, with a subset including the direct GLI1 binder GANT61 demonstrating activity in vivo. Further, we have also shown that GLI1 is directly phosphorylated by the kinase DYRK1A at a site within its putative nuclear localization sequence suggesting a possible mechanistic role in modulating its function. Utilizing the BRITE Institute’s capabilities in high-throughput screening we have identified novel and potent DYRK1A inhibitors that are being assessed for cellular and in vivo efficacy.

    Learning Objectives:

    1. Understand some of the new and novel approaches to targeting inflammatory breast cancer
    2. Understand why there are limited treatment options for IBC


    Show Resources
    You May Also Like
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources
    Attendees
    • See more